Biosimilars: what do patients need to consider?

A view from the EULAR Standing Committee of People with Arthritis/Rheumatism in Europe (SCPARE) on some of the issues that patients might wish to consider about biosimilars in shared decision-making discussions with their rheumatologist. The paper also points to the need for more information on bios...

Descripción completa

Detalles Bibliográficos
Autor principal: Skingle, Diana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Treatments
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4623364/
https://www.ncbi.nlm.nih.gov/pubmed/26535149
http://dx.doi.org/10.1136/rmdopen-2015-000141
_version_ 1782397673678045184
author Skingle, Diana
author_facet Skingle, Diana
author_sort Skingle, Diana
collection PubMed
description A view from the EULAR Standing Committee of People with Arthritis/Rheumatism in Europe (SCPARE) on some of the issues that patients might wish to consider about biosimilars in shared decision-making discussions with their rheumatologist. The paper also points to the need for more information on biosimilars being made available in lay language.
format Online
Article
Text
id pubmed-4623364
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-46233642015-11-03 Biosimilars: what do patients need to consider? Skingle, Diana RMD Open Treatments A view from the EULAR Standing Committee of People with Arthritis/Rheumatism in Europe (SCPARE) on some of the issues that patients might wish to consider about biosimilars in shared decision-making discussions with their rheumatologist. The paper also points to the need for more information on biosimilars being made available in lay language. BMJ Publishing Group 2015-09-16 /pmc/articles/PMC4623364/ /pubmed/26535149 http://dx.doi.org/10.1136/rmdopen-2015-000141 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Treatments
Skingle, Diana
Biosimilars: what do patients need to consider?
title Biosimilars: what do patients need to consider?
title_full Biosimilars: what do patients need to consider?
title_fullStr Biosimilars: what do patients need to consider?
title_full_unstemmed Biosimilars: what do patients need to consider?
title_short Biosimilars: what do patients need to consider?
title_sort biosimilars: what do patients need to consider?
topic Treatments
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4623364/
https://www.ncbi.nlm.nih.gov/pubmed/26535149
http://dx.doi.org/10.1136/rmdopen-2015-000141
work_keys_str_mv AT skinglediana biosimilarswhatdopatientsneedtoconsider

Ejemplares similares